7 results
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
Normal and Renal Dosing ... Inhibitors #Renal #Dosing ... #Pharmacology # ... Management #Diabetes ... #DM2 #Endocrinology
IDSA 2017 CDiff Guidelines - Table 7. Potential Treatment Agents for Treatment of the Primary Clostridium difficile
IDSA 2017 CDiff ... Guidelines - Table ... Clostridium difficile infection ... Episode #Pharmacology ... #Management #CDiff
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
GLP-1 Agonist Dosing ... oral route by using ... drug to remain stable ... semaglutide #Diabetes #Pharmacology ... #Endocrinology
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
are contacts of infectious ... p-Aminosalicylic acid, High-dose ... Tuberculosis #MDRTB #management ... antimicrobials #regimens #pharmacology ... #dosing #idsa #
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
IDSA Recommendations ... best prevented by using ... ) for 1–4 doses ... Prevention #Treatment #management ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... months or • RFB (dose ... Please refer to the table ... Prevention #Treatment #management ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
please refer to Table ... 5 for dosing recommendation ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology